The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 16, 2018

Filed:

Feb. 12, 2015
Applicant:

The United States of America, As Represented BY the Secretary of Agriculture, Washington, DC (US);

Inventors:

David M. Donovan, Baltimore, MD (US);

Lorena Rodriguez Rubio, Austrias, ES;

Beatriz Martinez Fernandez, Austrias, ES;

Ana Rodriguez, Austrias, ES;

Pilar Garcia Suarez, Austrias, ES;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/40 (2006.01); C12N 9/48 (2006.01); A61K 38/54 (2006.01); C12N 9/14 (2006.01); C12N 9/52 (2006.01); A61K 38/47 (2006.01); A61K 38/48 (2006.01);
U.S. Cl.
CPC ...
C12N 9/485 (2013.01); A61K 38/47 (2013.01); A61K 38/4813 (2013.01); A61K 38/4886 (2013.01); A61K 38/54 (2013.01); C12N 9/14 (2013.01); C12N 9/52 (2013.01); C07K 2319/00 (2013.01); C12Y 302/01017 (2013.01); C12Y 304/19011 (2013.01); C12Y 304/24075 (2013.01);
Abstract

Virion-associated peptidoglycan hydrolases have a potential as antimicrobial agents due to their ability to lyse Gram positive bacteria on contact. Fusion proteins HydH5SH3b and HydH5Lyso comprising full-length peptidoglycan hydrolase HydH5 from thebacteriophage vB_SauS-phi-IPLA88 in combination with the SH3b cell wall-binding domain from lysostaphin or full length lysostaphin, respectively, exhibited high lytic activity against livecells. CHAPSH3b, a HydH5 CHAP (cysteine, histidine-dependent amidohydrolase/peptidase) domain from truncated HydH5 in combination with the SH3b domain of lysostaphin, exhibited the highest lytic activity against livecells. HydH5 and its derivative fusions lysed bovine and human, methicillin-resistant(MRSA) N315 strain, and humanstrains in zymogram, plate lysis and turbidity reduction assays. HydH5 and its derivative fusions displayed antimicrobial synergy with the endolysin LysH5 (also encoded by vB_SauS-phi-IPLA88) in vitro suggesting the two enzymes have distinct cut sites and thus may be more efficient in combination for elimination of staphylococcal infections.


Find Patent Forward Citations

Loading…